John H. Rex
Chief Tech/Sci/R&D Officer at F2G Ltd.
Network origin in John H. Rex first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Advent Venture Partners LLP
 Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom.
24
| Private Company | Investment Managers | 24 |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.
12
| Holding Company | Pharmaceuticals: Major | 12 |
AstraZeneca GmbH
 AstraZeneca GmbH Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, AstraZeneca GmbH is a German pharmaceutical company that manufactures and sells pharmaceutical drugs. The company is based in Wedel, Germany. The company was founded in 1999. The CEO is Hans Sijbesma.
2
| Subsidiary | Pharmaceuticals: Major | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to John H. Rex via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| BIOGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Sales & Marketing Corporate Officer/Principal | |
| CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member Chief Operating Officer Sales & Marketing | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
| GALAPAGOS NV | Biotechnology | Chairman Director/Board Member | |
| AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member Director/Board Member Chairman | |
Artax Biopharma, Inc.
 Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | Medical Specialties | Director/Board Member Director/Board Member Corporate Officer/Principal | |
Zikani Therapeutics, Inc.
 Zikani Therapeutics, Inc. Drugstore ChainsRetail Trade Zikani Therapeutics, Inc. is a preclinical-stage company developing and commercializing novel therapeutics. The company was founded by Lawrence G. Miller and Andrew G. Myers in 2014 and is headquartered in Watertown, MA. | Drugstore Chains | Director/Board Member Chairman | |
| Stramongate SA | Investment Trusts/Mutual Funds | Chairman | |
Johnson & Johnson Innovation - JJDC, Inc.
 Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | Investment Managers | Private Equity Investor | |
| The Trustees of Columbia University in The City of New York | College/University | Graduate Degree Masters Business Admin | |
| University of Oxford | College/University | Corporate Officer/Principal Graduate Degree Undergraduate Degree | |
| University of Cambridge | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Corporate Officer/Principal | |
| University of London | College/University | Doctorate Degree Graduate Degree | |
Chroma Therapeutics Ltd.
 Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Chairman Chief Executive Officer | |
| University College London | College/University | Undergraduate Degree Doctorate Degree | |
| University of Bocconi | College/University | Undergraduate Degree | |
Axonics Women's Health Ltd.
 Axonics Women's Health Ltd. Pharmaceuticals: MajorHealth Technology Contura Ltd. specializes in the distribution and sale of healthcare products, both in pharmaceuticals and medical devices. The firm focuses in the fields of urology and urogynaecology. Its products include bulkamid, cystistat, and aquamid. The company was founded by Henry Geoffrey McMillan in 2000 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Avila Therapeutics, Inc.
 Avila Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Avila Therapeutics, Inc. researches and develops covalent drugs. The company was founded in 2007 and is headquartered in Summit, NJ. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Founder | |
Nicoventures Trading Ltd.
 Nicoventures Trading Ltd. Industrial ConglomeratesProducer Manufacturing Nicoventures Trading Ltd. researches, develops, manufactures and delivers tobacco harm reduction products and services. The firm provides innovative and sustainable solutions to global problems arising from smoking and smoking-related illnesses. The company develops ortfolio of products and services focused on smoking cessation and harm reduction, including user-friendly nicotine delivery systems and patient-focused smoking cessation and support services. The company was founded by Christopher John Lord and David Thomas Newns in September 2008 and is headquartered in Manchester, the United Kingdom. | Industrial Conglomerates | Chairman Director/Board Member | |
Advent Life Sciences LLP
 Advent Life Sciences LLP BiotechnologyHealth Technology Part of Advent Venture Partners LLP, Advent Life Sciences LLP is a venture capital firm for visionary innovators. The company is based in London, UK. Advent Life Sciences has achieved its first discovery milestone in collaboration with Bristol Myers Squibb, and is focused on the journey from innovative science to an approved medicine or product. The British company has a history of delivering value and is one of the leading venture capital firms in the industry. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Director/Board Member Private Equity Analyst Corporate Officer/Principal | |
NeRRe Therapeutics Ltd.
 NeRRe Therapeutics Ltd. Medical DistributorsDistribution Services NeRRe Therapeutics Ltd. provides clinical and pre clinical drugs for treatment of neuronal hypersensitivity. It develops neurokinin receptor antagonists acquired from GlaxoSmithKline. The company was founded by Emiliangelo Ratti and Mike Trower in 2012 and is headquartered in Stevenage, the United Kingdom. | Medical Distributors | Director/Board Member Director/Board Member | |
Pulmocide Ltd.
 Pulmocide Ltd. Pharmaceuticals: MajorHealth Technology Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Luxfold S.A.
 Luxfold S.A. BiotechnologyHealth Technology Luxfold S.A. designs and engineers protein structures. It offers protein three-dimensional structure. The company is headquartered in Luxembourg. | Biotechnology | Director/Board Member Founder | |
Amolyt Pharma SAS
 Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Onward Medical SA
 Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | Biotechnology | Director/Board Member | |
GTX medical BV
 GTX medical BV BiotechnologyHealth Technology GTX medical BV engages in the development of medical devices for targeted epidural spinal stimulation therapy. The company was founded by Jocelyne Bloch, Sjaak Deckers, and Grégoire Courtine in December 2014 and is headquartered in Eindhoven, the Netherlands. | Biotechnology | Director/Board Member | |
NMD Pharma A/S
 NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Biotechnology | Chairman Director/Board Member | |
Orphalan SA
 Orphalan SA Pharmaceuticals: MajorHealth Technology GMP-Orphan SA engages in the research and development in biotechnology. It focuses on developing and designing drugs for life-threatening and rare diseases. The company was founded by Frederic Marin on July 18, 2011 and is headquartered in Paris, France. | Pharmaceuticals: Major | Chairman Chairman Director/Board Member Chief Executive Officer | |
Arrakis Therapeutics, Inc.
 Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Founder Founder Chairman Founder | |
| ELOXX PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Syndesi Therapeutics SA
 Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
Calypso Biotech BV
 Calypso Biotech BV BiotechnologyHealth Technology Calypso Biotech BV operates as immunotherapy biotech company. It develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Amsterdam, the Netherlands. | Biotechnology | Director/Board Member | |
Anaveon AG
 Anaveon AG BiotechnologyHealth Technology Anaveon AG engages in the development of immune therapies against cancer. Its compounds promote effector T-cell functions to enhance a patient?s immune system to respond to tumors. The company was founded on December 11, 2017 by Onur Boyman and Andreas Katopodis and is headquartered in Bottmingen, Switzerland. | Biotechnology | Director/Board Member Director/Board Member | |
Aleta Biotherapeutics, Inc.
 Aleta Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aleta Biotherapeutics, Inc. engages in the immuno-oncology service that focuses on transforming cellular therapeutics. It allows broad spectrum of cancer indication to be targeted including currently intractable solid tumors. The company was founded by Paul Rennert and Roy Lobb and is headquartered in Natick, MA. | Miscellaneous Commercial Services | Director/Board Member Founder Chief Executive Officer | |
Tridek-One Therapeutics SAS
 Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
| HANSA INVESTMENT COMPANY LIMITED | Investment Managers | Director/Board Member | |
Pheno Therapeutics Ltd.
 Pheno Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Pheno Therapeutics Ltd. operates as a biotechnology company. The firm develops remyelinating therapies for the unmet need for a neuroprotective therapy for multiple sclerosis. The company was founded on October 31, 2018 and is headquartered in Edinburgh, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer Chief Executive Officer | |
Mestag Therapeutics Ltd.
 Mestag Therapeutics Ltd. Financial ConglomeratesFinance Mestag Therapeutics Ltd. is engaged in the biotechnology industry. The company was founded on February 17, 2020 and is headquartered in Cambridge, the United Kingdom. | Financial Conglomerates | Director/Board Member | |
Apollo Therapeutics LLP
 Apollo Therapeutics LLP Financial ConglomeratesFinance Apollo Therapeutics LLP is a British biopharmaceutical company that focuses on translating medical research into medicines. The company is based in Stevenage, UK. The company has a portfolio-model built around a centralized management team of experts in pharmaceutical R&D, manufacturing, commercial strategy, fundraising, and business development. The company's assets are housed in separate wholly-owned subsidiary companies, which incorporate best practices from big pharma and venture capital. The company has a scalable R&D platform for the discovery and development of new medicines, enabled by access to five of the world's leading universities and research institutes. The company was founded in 2015, and the CEO is Richard Mason. | Financial Conglomerates | Consultant / Advisor | |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member Director/Board Member | |
| ONWARD MEDICAL N.V. | Miscellaneous Commercial Services | Director/Board Member | |
| F2g Inc. | Director/Board Member President |
Statistics
International
| United States | 17 |
| United Kingdom | 17 |
| Switzerland | 6 |
| France | 4 |
| Netherlands | 4 |
Sectoral
| Health Technology | 29 |
| Consumer Services | 7 |
| Finance | 6 |
| Commercial Services | 6 |
| Retail Trade | 2 |
Operational
| Director/Board Member | 223 |
| Corporate Officer/Principal | 76 |
| Chairman | 53 |
| Independent Dir/Board Member | 36 |
| Private Equity Investor | 32 |
Most connected contacts
| Insiders | |
|---|---|
| Raj Bhikhu Parekh | 50 |
| Patrick Volkert Vink | 30 |
| Sylvie Grégoire | 25 |
| Mohammed Malik | 24 |
| Fiona MacLaughlin | 22 |
| Dale Pfost | 22 |
| Ian James Nicholson | 20 |
| Alan Walts | 17 |
| Simona Heidempergher | 16 |
| Katrine Bosley | 15 |
| Anderson Timothy | 13 |
| Satish Jindal | 13 |
| Donald Lee Drakeman | 13 |
| Dominic Schmidt | 12 |
| Naveed Iqbal Siddiqi | 12 |
- Stock Market
- Insiders
- John H. Rex
- Company connections
